{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:42:52Z","timestamp":1789587772721,"version":"build-2803163510"},"reference-count":54,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,2]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies differentially affect men and women with PsA remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effect of sex on the long-term persistence of each class of targeted therapies in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. We included all adults with PsA who were new users of targeted therapies (not in the year before the index date) during 2015\u20132021 and studied all treatment lines during the study period. Persistence was defined as the time from treatment initiation to discontinuation and was estimated by the Kaplan-Meier method. Comparison of persistence by sex involved multivariate frailty models with conventional synthetic disease-modifying antirheumatic drugs and prednisone as time-dependant variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 14\u2009778 patients with PsA who were new users of targeted therapies: 8475 (57%) women (mean age 50\u00b113 years; 15\u2009831 lines), 6303 (43%) men (mean age 51\u00b113 years; 10\u2009488 lines). Overall, 1-year persistence was 52% for women and 62% for men and at 3 years it was 27% and 39%, respectively. After adjustments, persistence was lower for women than men for inhibitors of tumour necrosis factor (TNFi) (adjusted HR (HR<jats:sub>a<\/jats:sub>) 1.4, 99% CI 1.3 to 1.5) and interleukin 17 inhibitor (IL17i) (HR<jats:sub>a<\/jats:sub> 1.2, 99% CI 1.1 to 1.3) but not IL12\/23i (HR<jats:sub>a<\/jats:sub> 1.1, 99% CI 0.9 to 1.3), IL23i (HR<jats:sub>a<\/jats:sub> 1.1, 99% CI 0.7 to 1.5) or Janus kinase inhibitor (JAKi) (HR<jats:sub>a<\/jats:sub> 1.2, 99% CI 0.9 to 1.6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The treatment persistence was lower for women than men for TNFi and IL17i but not for IL12\/23i, IL23i or JAKi.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003570","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:15:42Z","timestamp":1702988142000},"page":"e003570","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-1148","authenticated-orcid":false,"given":"Laura","family":"Pina Vegas","sequence":"first","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Service de Rhumatologie, Hopital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Penso","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Inserm, Centre d\u2019investigation clinique 1430, Hopital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-0544","authenticated-orcid":false,"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[{"name":"EpiDermE, Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Cr\u00e9teil, France"},{"name":"Service de Rhumatologie, Hopital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2025090313332417000_9.4.e003570.1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313332417000_9.4.e003570.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214065"},{"key":"2025090313332417000_9.4.e003570.3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/art.41741","article-title":"The epidemiology of psoriatic arthritis over five decades: a population-based study","volume":"73","author":"Karmacharya","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313332417000_9.4.e003570.4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090313332417000_9.4.e003570.5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313332417000_9.4.e003570.6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","article-title":"Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database","volume":"60","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313332417000_9.4.e003570.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201357"},{"key":"2025090313332417000_9.4.e003570.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.17666"},{"key":"2025090313332417000_9.4.e003570.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313332417000_9.4.e003570.10","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates","year":"2022","journal-title":"J Rheumatol"},{"key":"2025090313332417000_9.4.e003570.11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313332417000_9.4.e003570.12","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French society for rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including Psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2025090313332417000_9.4.e003570.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"2025090313332417000_9.4.e003570.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"2025090313332417000_9.4.e003570.15","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","article-title":"Retention rates and identification of factors associated with anti-TNF\u03b1, anti-Il17, and anti-Il12\/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting","volume":"39","author":"Navarini","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090313332417000_9.4.e003570.16","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-Il12\/23, or anti-Il17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025090313332417000_9.4.e003570.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key140"},{"key":"2025090313332417000_9.4.e003570.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2025090313332417000_9.4.e003570.19","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"2025090313332417000_9.4.e003570.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"key":"2025090313332417000_9.4.e003570.21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ced\/llac098","article-title":"Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents","volume":"48","author":"Roccuzzo","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2025090313332417000_9.4.e003570.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002718","article-title":"Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension","volume":"9","author":"Eder","year":"2023","journal-title":"RMD Open"},{"key":"2025090313332417000_9.4.e003570.23","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the Syst\u00e8me national D\u2019Information Interr\u00e9gimes de L\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me national des Donn\u00e9es de Sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2025090313332417000_9.4.e003570.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of Urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"2025090313332417000_9.4.e003570.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"2025090313332417000_9.4.e003570.26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2302134","article-title":"Stroke, myocardial infarction, and pulmonary embolism after bivalent booster","volume":"388","author":"Jabagi","year":"2023","journal-title":"N Engl J Med"},{"key":"2025090313332417000_9.4.e003570.27","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/ene.15423","article-title":"Risk of intracranial meningioma with three potent progestogens: a population-based case-control study","volume":"29","author":"Hoisnard","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025090313332417000_9.4.e003570.28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jama.2022.21471","article-title":"Association between doses of levonorgestrel intrauterine systems and subsequent use of psychotropic drugs in France","volume":"329","author":"Roland","year":"2023","journal-title":"JAMA"},{"key":"2025090313332417000_9.4.e003570.29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"2025090313332417000_9.4.e003570.30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00985760"},{"key":"2025090313332417000_9.4.e003570.31","unstructured":"Inserm . Available: https:\/\/www.inserm.fr\/dossier\/menopause\/"},{"key":"2025090313332417000_9.4.e003570.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090313332417000_9.4.e003570.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000596","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis data from the British society for rheumatology biologics register","volume":"4","author":"Fagerli","year":"2018","journal-title":"RMD Open"},{"key":"2025090313332417000_9.4.e003570.34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313332417000_9.4.e003570.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313332417000_9.4.e003570.36","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025090313332417000_9.4.e003570.37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/09546634.2017.1329504","article-title":"Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary","volume":"28","author":"Pog\u00e1cs\u00e1s","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2025090313332417000_9.4.e003570.38","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/rheumatology\/kead089","article-title":"Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data","volume":"62","author":"Van Kuijk","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313332417000_9.4.e003570.39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","article-title":"Psoriatic arthritis in males and females: differences and similarities","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313332417000_9.4.e003570.40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217938","article-title":"Molecular mechanisms of sex-related differences in arthritis and associated pain","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025090313332417000_9.4.e003570.41","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90"},{"key":"2025090313332417000_9.4.e003570.42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313332417000_9.4.e003570.43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J Clin Med"},{"key":"2025090313332417000_9.4.e003570.44","doi-asserted-by":"crossref","DOI":"10.1186\/1475-9276-8-14","article-title":"Better science with sex and gender: facilitating the use of a sex and gender-based analysis in health research","volume":"8","author":"Johnson","year":"2009","journal-title":"Int J Equity Health"},{"key":"2025090313332417000_9.4.e003570.45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025090313332417000_9.4.e003570.46","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13923"},{"key":"2025090313332417000_9.4.e003570.47","unstructured":"Murage M , Tongbram V , Feldman S , et al . Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review"},{"key":"2025090313332417000_9.4.e003570.48","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jid.2023.03.1660","article-title":"First-line persistence of biologics in psoriasis from a cohort based on French medico-administrative data","volume":"143","author":"Marcombes","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025090313332417000_9.4.e003570.49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025090313332417000_9.4.e003570.50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14737167.2018.1512408","article-title":"Adherence and resource use among psoriasis patients treated with biologics","volume":"18","author":"Aleshaki","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025090313332417000_9.4.e003570.51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PSA patients starting TNF inhibitor treatment-results from 12 countries in Eurospa","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313332417000_9.4.e003570.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"2025090313332417000_9.4.e003570.53","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"2025090313332417000_9.4.e003570.54","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.495"}],"updated-by":[{"DOI":"10.1136\/rmdopen-2023-003570corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000}}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:33:35Z","timestamp":1756931615000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/rmdopen-2023-003570"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003570","relation":{"correction":[{"id-type":"doi","id":"10.1136\/rmdopen-2023-003570corr1","asserted-by":"object"}]},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}